%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Bioqual Inc?
provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
BIOQ · Verdict
Moderate reward · moderate risk
BIOQ stands out on balance sheet and valuation, but watch the profitability signal.
Based on 88% data coverage
BIOQ · Verdict
What’s working & what to watch
Strengths 3
- Balance sheet100/100
Current ratio 3.72
- Valuation77/100
Above average
- Volatility75/100
Above average
Watchouts 3
- Profitability21/100
-2% net margin · -3% ROE
- Growth43/100
Revenue -9.6% CAGR
- Cash flow45/100
6% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
What is Bioqual Inc?
provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 33.05M, and a P/E ratio of 15.6x.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (45)The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.